Beijing InnoCare Pharma Tech Co., Ltd.   Report issue

For profit Phase 1 Phase 2 Phase 3
Founded: Beijing China (2001)

Organization Overview

First Clinical Trial
2017
NCT03189017
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2023

Timeline

NOW
  • Now

Alternative names

Beijing InnoCare Pharma Tech Co., Ltd. | Innocare Pharma Australia Pty Ltd | InnoCare Pharma Inc.

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Cholangiocarcinoma (Phase 2)

Leukemia (Phase 3)

Leukemia, Lymphocytic, Chronic, B-Cell (Phase 3)

Leukemia, Lymphoid (Phase 3)

Lupus Erythematosus, Systemic (Phase 2)

Lymphoma (Phase 3)

Lymphoma, B-Cell (Phase 2)

Lymphoma, B-Cell, Marginal Zone (Phase 2)

Lymphoma, Large B-Cell, Diffuse (Phase 2)

Lymphoma, Mantle-Cell (Phase 2)

Neoplasm Metastasis (Phase 2)

Neoplasms (Phase 2)

Waldenstrom Macroglobulinemia (Phase 2)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 44
  • # of Trial APIs: 23